Recommendations on dose level selection for repeat dose toxicity studies

被引:11
|
作者
Sewell, Fiona [1 ]
Corvaro, Marco [2 ]
Andrus, Amanda [3 ]
Burke, Jonathan [4 ]
Daston, George [5 ]
Delaney, Bryan [6 ]
Domoradzki, Jeanne [7 ]
Forlini, Carole [8 ]
Green, Maia Louise [9 ]
Hofmann, Thomas [10 ]
Jackel, Sven [11 ]
Lee, Moung Sook [12 ]
Temerowski, Michael [13 ]
Whalley, Paul [14 ]
Lewis, Richard [14 ]
机构
[1] Natl Ctr Replacement Refinement & Reduct Anim Res, Gibbs Bldg,215 Euston Rd, London NW1 2BE, England
[2] Corteva Agrisci Italia SRL, Rome, Italy
[3] Dow Chem Co USA, Midland, MI 48674 USA
[4] Reckitt, Kingston Upon Hull, N Humberside, England
[5] Procter & Gamble Co, Cincinnati, OH USA
[6] Firmenich, Plainsboro, NJ USA
[7] Corteva Agrisci, Indianapolis, IN USA
[8] Arkema, Colombes, France
[9] ExxonMobil Biomed Sci Inc, Annandale, NJ USA
[10] BASF SE, Ludwigshafen, Germany
[11] Merck KGaA, Darmstadt, Germany
[12] Clariant, Sulzbach, Germany
[13] Bayer Crop Sci, Mannheim, Germany
[14] Syngenta Ltd, Bracknell, Berks, England
关键词
Dose selection; Toxicokinetics; Exposure; 3Rs; HAZARD ASSESSMENT; SAFETY;
D O I
10.1007/s00204-022-03293-3
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Prior to registering and marketing any new pharmaceutical, (agro)chemical or food ingredient product manufacturers must, by law, generate data to ensure human safety. Safety testing requirements vary depending on sector, but generally repeat-dose testing in animals form the basis for human health risk assessments. Dose level selection is an important consideration when designing such studies, to ensure that exposure levels that lead to relevant hazards are identified. Advice on dose level selection is provided in test guidelines and allied guidance documents, but it is not well harmonised, particularly for selection of the highest dose tested. This paper further builds on concepts developed in a technical report by the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC) which recommends pragmatic approaches to dose selection considering regulatory requirements, animal welfare and state of the art scientific approaches. Industry sectors have differing degrees of freedom to operate regarding dose level selection, depending on the purpose of the studies and the regulatory requirements/legislation, and this is reflected in the overall recommended approaches. An understanding of systemic exposure should be utilised where possible (e.g., through toxicokinetic approaches) and used together with apical endpoints from existing toxicity studies to guide more appropriate dose level selection. The highest dose should be limited to a reasonable level, causing minimal but evident toxicity to the test animals without significantly compromising their well-being. As the science of predictive human exposure further develops and matures, this will provide exciting and novel opportunities for more human-relevant approaches to dose level selection.
引用
收藏
页码:1921 / 1934
页数:14
相关论文
共 50 条
  • [41] A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats
    Takizawa, T
    Hasimoto, K
    Itoh, N
    Yamashita, S
    Owen, K
    HUMAN & EXPERIMENTAL TOXICOLOGY, 1999, 18 (01): : 38 - 45
  • [42] Repeat dose study to investigate the toxicity of doxorubicin in the female Han Wistar rat
    Brady, S
    York, M
    Clements, P
    Whayman, M
    Chen, C
    Williams, T
    Griffiths, WL
    Patterson, L
    Nash, A
    Roman, I
    Turton, J
    TOXICOLOGY, 2004, 202 (1-2) : 77 - 78
  • [43] Repeat-dose and embryo-fetal developmental toxicity of zinpentraxin alfa
    Rao, Gautham K.
    Santagostino, Sara F.
    Wong, Lisa
    Inoue, Ayumi
    Arjomandi, Audrey
    Yadav, Rajbharan
    Halpern, Wendy G.
    REPRODUCTIVE TOXICOLOGY, 2024, 123
  • [44] Repeat dose study to investigate the toxicity of doxorubicin in the female Han Wistar rat
    Monokrousou, D
    Brady, S
    Chung, S
    Green, L
    York, M
    Clements, P
    Roman, I
    Swain, A
    Stamp, C
    Williams, T
    Evans, G
    Griffiths, W
    Patterson, L
    Turton, J
    TOXICOLOGY, 2005, 213 (03) : 245 - 245
  • [45] Analysis of target organs in repeated dose toxicity studies
    Escher, S.
    Batke, M.
    Bitsch, A.
    Licht, O.
    Melber, C.
    Simetska, N.
    Mangelsdorf, I
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2009, 379 : 91 - 91
  • [46] Personalized dose selection in radiation therapy using statistical models for toxicity and efficacy with dose and biomarkers as covariates
    Schipper, Matthew J.
    Taylor, Jeremy M. G.
    TenHaken, Randy
    Matuzak, Martha M.
    Kong, Feng-Ming
    Lawrence, Theodore S.
    STATISTICS IN MEDICINE, 2014, 33 (30) : 5330 - 5339
  • [47] Acute toxicity studies and determination of median lethal dose
    Akhila, J. Shetty
    Shyamjith, Deepa
    Alwar, M. C.
    CURRENT SCIENCE, 2007, 93 (07): : 917 - 920
  • [48] Utility-Based Dose Selection for Phase II Dose-Finding Studies
    Aouni, Jihane
    Bacro, Jean Noel
    Toulemonde, Gwladys
    Colin, Pierre
    Darchy, Loic
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (04) : 818 - 840
  • [49] Utility-Based Dose Selection for Phase II Dose-Finding Studies
    Jihane Aouni
    Jean Noel Bacro
    Gwladys Toulemonde
    Pierre Colin
    Loic Darchy
    Therapeutic Innovation & Regulatory Science, 2021, 55 : 818 - 840
  • [50] Inclusion of telemetry cardiovascular parameters in small molecule repeat-dose toxicity studies, a potential refinement in animal use
    Stevens, Dale W.
    Wong, Lisa P.
    Schutt, Leah
    Gelzleichter, Tom
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2019, 99